4x the Performance, Zero Compromise: How Functionalized Polymers Are Changing the Rules
Free Case StudyDeveloping a Stable Specialty Polymer for Use in Energy Applications Discover how Syngene helped Notark turn an idea…
Syngene
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
The $100bn frontier: Untapped potential in animal health innovation
Harnessing artificial intelligence and digital technologies across the biopharma value chain
Inside the growing precision therapy market and the crucial role of pDNA manufacturing
ADCs as biological missiles for targeted therapies
Sustainability in the pharma industry: The way forward
High biologics demand spurs need for greater contract manufacturing
